Neovasc NVCN 深 沪
等待开盘 11-10 09:30:00 美东时间
30.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 30.03
- 总市值 8359.15万
- 52周最高 30.07
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.585
- 委 比 0.00%
- 总股本 278.36万
- 历史最高 253000.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.25
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
EyePoint, Inc. will participate in several conferences and scientific meetings in November and December 2026 to discuss its innovative therapeutics for retinal diseases, including presentations on pivotal Phase 3 trial results for EYP-1901 in Wet AMD and DME. The company will present at the Guggenheim 3rd Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, Jefferies 2026 Global Healthcare Conference in London, and UBS Glob...
11-06 12:00
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
Ocular Therapeutix, Inc. will participate in several conferences in October 2026, including the Chardan 10th Annual Healthcare Conference on October 20, 2026, and multiple scientific sessions at Eyecelerator @ AAO 2026, Innovate Retina, and the American Academy of Ophthalmology events in New Orleans. Presentations will cover Phase 3 trial updates for AXPAXLI™ (OTX-TKI) in wet AMD and other retina-related topics. A live webcast of the Chardan fire...
10-01 11:00
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
Ocular Therapeutix, Inc. announced its participation in several investor and scientific conferences in September and October 2026. The company will host investor meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston and the Baird Global Healthcare Conference in New York. Additionally, Ocular Therapeutix will present at the Retina Society Annual Meeting, Ophthalmology Futures Forums, and Euretina Congress in Vienna, focusing on i...
09-01 11:00
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow announced the presentation of three studies supporting IHEEZO® and BYOOVIZ® at the ASRS 2026 Annual Meeting. The studies expand clinical and real-world evidence for Harrow's retina portfolio. IHEEZO showed promising trends in reducing post-procedure pain and improving patient experience, while BYOOVIZ demonstrated safety and effectiveness in real-world use. Harrow emphasized its commitment to generating quality evidence to support long-ter...
07-20 11:00
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Therapeutics announced positive additional data from its Phase 1a single ascending dose (SAD) trial of TH103 in neovascular age-related macular degeneration (AMD). Expanded cohorts showed sustained improvements in vision, retinal anatomy, and pharmacokinetics, supporting extended treatment durability. TH103 demonstrated greater intraocular retention compared to leading anti-VEGF agents, with 41% of treatment-naive patients requiring retre...
07-17 11:00
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix, Inc. will participate in several scientific and investor conferences in July 2026, including the OIS Retina Innovation Summit and the ASRS Annual Meeting in Montréal. Key presentations will focus on retinal disease treatments, including data from the Phase 3 SOL-1 trial for axitinib hydrogel (OTX-TKI) in neovascular AMD. The company will also host a fireside chat at the HC Wainwright Ophthalmology Virtual Conference. Ocular is...
07-01 11:00
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics will present a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada, on July 18, 2026. The presentation, titled "2-Year Follow-Up: PRISM Phase 2b Clinical Trial Evaluating Investigational 4D-150, an Intravitreal Gene Therapy, in a Broad Neovascular AMD Population," will discuss the long-term results of their gene therapy for neovascular age-rel...
06-30 20:05
Kalaris to Present at Clinical Trials at the Summit 2026
Kalaris Therapeutics will present Phase 1a clinical data for TH103, a novel dual-targeting biologic, at CTS 2026 on June 13, 2026. The presentation, led by Karl Csaky, MD, PhD, will showcase results from treatment-naïve patients with neovascular AMD. TH103, developed by Dr. Napoleone Ferrara, targets VEGF and HSPG to enhance intraocular retention and VEGF inhibition, with potential applications for wet AMD, diabetic eye disease, and retinal vein ...
06-12 12:00
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Ocular Therapeutix, Inc. will participate in Clinical Trials at the Summit 2026 in Las Vegas, presenting updates on its OTX-TKI product candidate for retinal diseases, including wet AMD and diabetic retinopathy. The company will also discuss its pipeline leveraging ELUTYX technology, with DEXTENZA approved for ocular inflammation and OTX-TIC in Phase 2 for glaucoma. Exact presentation times may change.
06-04 11:00
Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal
06-01 20:48
